Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

Could a new glioblastoma treatment improve survival rates?

Researchers have completed patient enrollment for a clinical study evaluating TLX101-Tx, a new treatment for glioblastoma, a particularly aggressive form of brain cancer. The IPAX-2 study has shown promising results, with no dose-limiting toxicities reported as patients received the maximum dose of the treatment. This targeted radiopharmaceutical therapy aims to improve outcomes for individuals newly diagnosed with glioblastoma by combining it with standard post-surgical treatments.

For those interested in healthy aging and longevity, this development could represent a significant advancement in cancer care. Glioblastoma has a poor prognosis, with most patients surviving only 12 to 15 months after diagnosis. TLX101-Tx could potentially enhance survival rates and quality of life for patients facing this challenging diagnosis, especially since it is designed to cross the blood-brain barrier effectively.

The IPAX-2 study is an early-stage trial focused on safety and tolerability, involving 12 patients across multiple countries. While the absence of severe side effects is encouraging, more extensive trials are needed to confirm the treatment’s effectiveness in improving survival rates. Additionally, TLX101-Tx is also being tested in a pivotal trial called IPAX BrIGHT, which is assessing its efficacy in patients with recurrent glioblastoma.

If you or someone you know is facing a glioblastoma diagnosis, it may be worth discussing emerging treatments like TLX101-Tx with healthcare providers. Staying informed about new therapies can help you make better decisions about treatment options.

Source: globenewswire.com